Results 131 to 140 of about 5,065,448 (337)

Detection of secretory IgA antibodies against gliadin and human tissue transglutaminase in stool to screen for coeliac disease in children: validation study [PDF]

open access: yes, 2006
Objective To evaluate two commercial stool tests for detection of secretory IgA antibodies against gliadin and human tissue transglutaminase for diagnosis of coeliac disease in children with symptoms.Setting Tertiary care children's hospital.Participants
Diehl, Veronika   +4 more
core   +2 more sources

Machine learning for identifying liver and pancreas cancers through comprehensive serum glycopeptide spectra analysis: a case‐control study

open access: yesMolecular Oncology, EarlyView.
This study presents a novel AI‐based diagnostic approach—comprehensive serum glycopeptide spectra analysis (CSGSA)—that integrates tumor markers and enriched glycopeptides from serum. Using a neural network model, this method accurately distinguishes liver and pancreatic cancers from healthy individuals.
Motoyuki Kohjima   +6 more
wiley   +1 more source

MULTIPLEX TISSUE ANALYSIS OF NEURONAL LINEAGE MARKERS IN DEVELOPING MOUSE BRAIN

open access: yesIBRO Neuroscience Reports, 2023
Eugenia Kuteeva, Mikael Malmqvist
doaj   +1 more source

An engineered human Fc domain that behaves like a pH-toggle switch for ultra-long circulation persistence

open access: yesNature Communications, 2019
Lee et al. report an engineered IgG1 Fc domain that behaves like an hFcRn binding pH toggle switch. The authors show that this new half-life extension Fc domain confers improved pharmacokinetics in new humanized knock-in mouse strains that recapitulate ...
Chang-Han Lee   +18 more
doaj   +1 more source

Immunization expands B cells specific to HIV-1 V3 glycan in mice and macaques. [PDF]

open access: yes, 2019
Broadly neutralizing monoclonal antibodies protect against infection with HIV-1 in animal models, suggesting that a vaccine that elicits these antibodies would be protective in humans.
Abernathy, Morgan E   +31 more
core  

Combination therapy with anti-HIV-1 antibodies maintains viral suppression

open access: yesNature, 2018
Individuals infected with HIV-1 require lifelong antiretroviral therapy, because interruption of treatment leads to rapid rebound viraemia. Here we report on a phase 1b clinical trial in which a combination of 3BNC117 and 10-1074, two potent monoclonal ...
Pilar Mendoza   +35 more
semanticscholar   +1 more source

β‐TrCP overexpression enhances cisplatin sensitivity by depleting BRCA1

open access: yesMolecular Oncology, EarlyView.
Low levels of β‐TrCP (Panel A) allow the accumulation of BRCA1 and CtIP, which facilitate the repair of cisplatin‐induced DNA damage via homologous recombination (HR) and promote tumor cell survival. In contrast, high β‐TrCP expression (Panel B) leads to BRCA1 and CtIP degradation, impairing HR repair, resulting in persistent DNA damage and apoptosis ...
Rocío Jiménez‐Guerrero   +8 more
wiley   +1 more source

Rational Design of Chemically Controlled Antibodies and Protein Therapeutics [PDF]

open access: hybrid, 2023
Anthony Marchand   +8 more
openalex   +1 more source

Antibodies to watch in 2019

open access: yesmAbs, 2018
For the past 10 years, the annual ‘Antibodies to watch’ articles have provided updates on key events in the late-stage development of antibody therapeutics, such as first regulatory review or approval, that occurred in the year before publication or were
H. Kaplon, J. Reichert
semanticscholar   +1 more source

Nicotinamide N‐methyltransferase promotes drug resistance in lung cancer, as revealed by nascent proteomic profiling

open access: yesMolecular Oncology, EarlyView.
AZD9291 has shown promise in targeted cancer therapy but is limited by resistance. In this study, we employed metabolic labeling and LC–MS/MS to profile time‐resolved nascent protein perturbations, allowing dynamic tracking of drug‐responsive proteins. We demonstrated that increased NNMT expression is associated with drug resistance, highlighting NNMT ...
Zhanwu Hou   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy